Drug Discoveries and Therapeutics is a highly regarded journal devoted to the advancement of knowledge in the field of medicine and pharmacology. Published by the International Research & Cooperation Association for Biological & Socio-Sciences Advancement in Tokyo, Japan, this journal serves as a vital resource for researchers, practitioners, and students interested in the latest developments in drug discovery and therapeutic strategies. With a Scopus ranking of #192 out of 826 in the General Medicine category, and positioning itself in the 76th percentile, it demonstrates a significant impact within the scientific community. The journal publishes original research articles, reviews, and innovative studies that address the complexities of drug development, therapeutic efficacy, and clinical applications. Researchers and clinicians can access valuable insights to enhance their practices and inform further studies as it continues to disseminate crucial findings essential for the advancement of medical science.

Clinical Pharmacology in Drug Development, published by WILEY, is a distinguished journal dedicated to advancing the field of pharmaceutical science and drug development. With a strong commitment to disseminating cutting-edge research, this journal serves as a crucial platform for professionals, researchers, and students aiming to enhance their understanding of pharmacological principles and innovations in medical therapeutics. Since its inception in 2012, the journal has consistently maintained a noteworthy presence in the academic community, currently achieving a Q2 ranking in both Pharmaceutical Science and Medical Pharmacology categories as of 2023. Although the journal operates under a subscription model, it is highly regarded for its rigorous peer-reviewed publications, offering insights into drug efficacy, safety, and regulatory challenges. Positioned at the intersection of clinical practices and pharmaceutical advancements, Clinical Pharmacology in Drug Development plays an essential role in bridging the gap between scientific research and real-world application, ensuring that the latest therapeutic strategies are optimized for patient care.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, published by WILEY, serves as a vital resource in the fields of medicine, pharmacology, and toxicology. With an ISSN of 1742-7835 and E-ISSN 1742-7843, this journal has established a robust reputation, reflected in its Q2 classification across its categories in 2023. It aims to disseminate high-quality research and reviews that bridge the gap between basic scientific findings and clinical applications. Operating from the United States with an address at 111 RIVER ST, HOBOKEN 07030-5774, NJ, this journal focuses on the intersection of drug action and toxicity, making it an essential platform for researchers, healthcare professionals, and students. With a converged publication timeline from 2004 to 2024, BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY continues to make significant contributions to understanding pharmacological treatments and toxicological challenges. Open access options are available to broaden the reach and impact of its published work.

PHARMACOTHERAPY, an esteemed journal published by WILEY, stands as a pivotal resource within the field of medical pharmacology. With its ISSN 0277-0008 and E-ISSN 1875-9114, this journal has been at the forefront of pharmacological research since its inception in 1981. Renowned for its rigorous peer-review process and impactful contributions, it currently holds a prestigious Q1 quartile ranking in the pharmacology category, underscoring its significance as a leading publication in the field. It ranks #40 out of 272 journals in Scopus, placing it in the top 15% percentile of its category. While not an open-access publication, PHARMACOTHERAPY remains committed to advancing knowledge and understanding in pharmacological sciences, making it an indispensable resource for researchers, healthcare professionals, and students dedicated to improving therapeutic outcomes and drug utilization. Based in the United States, at 111 River St, Hoboken, NJ, the journal is poised to continue its impact through to 2024 and beyond, welcoming contributions that further the discourse in pharmacotherapy.

Translational and Clinical Pharmacology, published by KSCPT, is an esteemed journal that serves as a vital source of knowledge in the field of pharmacology, particularly focusing on the translational aspects that bridge laboratory research and clinical applications. Established in 2014, this journal aims to disseminate high-quality research and reviews pertaining to drug development, therapeutics, and the underlying mechanisms of action in the medical realm. With an ISSN of 2289-0882 and an E-ISSN of 2383-5427, it holds a significant position with a Q3 ranking in the pharmacology category as of 2023, emphasizing its role in advancing scientific understanding within this crucial discipline. While it operates as a traditional subscription-based journal, its output remains accessible through various academic platforms, contributing to the global discourse in pharmacology. Researchers, professionals, and students will find value in its insightful articles and comprehensive studies, underscoring the journal’s commitment to enhancing pharmacological knowledge and practice.

Expert Review of Clinical Pharmacology, published by TAYLOR & FRANCIS LTD, is a leading peer-reviewed journal dedicated to the field of clinical pharmacology, with a strong focus on the development and application of pharmacological therapies in patient care. Boasting an impressive impact, the journal ranks in the first quartile across multiple categories including Medicine (miscellaneous), Pharmacology (medical), and Pharmacology, Toxicology and Pharmaceutics (miscellaneous), reflecting its influential position within the scientific community. With a Scopus ranking of #6 in General Pharmacology, Toxicology and Pharmaceutics, the journal also achieves a commendable 93rd percentile, further emphasizing its importance as a resource for researchers and clinicians alike. As it continues to publish innovative reviews and research articles from 2008 until 2024, the Expert Review of Clinical Pharmacology plays an essential role in advancing knowledge, improving clinical practice, and fostering collaboration among experts in pharmacology, thereby driving forward the field's evolution towards better patient outcomes.

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, published by DUSTRI-VERLAG DR KARL FEISTLE in Germany, is a vital scholarly platform dedicated to advancing the field of pharmacology through rigorous research and innovative therapeutic strategies. Established in 1994, this journal has maintained its relevance in the evolving landscape of clinical pharmacology, achieving a Q3 rank in both general and medical pharmacology categories as of 2023. With an ISSN of 0946-1965, it is positioned as an essential resource for researchers, healthcare professionals, and students seeking to enhance their understanding of drug therapy and pharmacological applications. Though it currently does not offer open access, its comprehensive scope covers a wide array of topics within pharmacology, promising to contribute significantly to scientific discussions and knowledge dissemination from 1994 to 2024. Whether you are looking for the latest studies or historical insights, the journal remains a fixture for anyone invested in the pharmacological sciences.

BIOLOGICAL & PHARMACEUTICAL BULLETIN, published by the PHARMACEUTICAL SOC JAPAN, is a prominent peer-reviewed journal that serves the fields of medicine, pharmaceutical science, and pharmacology. With an ISSN of 0918-6158 and an E-ISSN of 1347-5215, this publication has been crucial in disseminating innovative research since its inception in 1993, and it continues to contribute significantly to the body of knowledge as it converges towards 2024. Despite being classified as a non-open access journal, it maintains a respectable Q3 ranking in Medicine (miscellaneous) and Q2 in Pharmaceutical Science, highlighting its critical role in advancing scientific discourse in these areas. With Scopus rankings placing it in the 51st percentile for Pharmaceutical Science and 38th percentile for Pharmacology, BIOLOGICAL & PHARMACEUTICAL BULLETIN is an essential resource for researchers, professionals, and students looking to stay abreast of cutting-edge developments and trends in biomedicine and drug development.

Welcome to the Journal of Clinical Pharmacology, an esteemed publication in the field of pharmacology and medical pharmacology, published by Wiley. Since its inception in 1973, this journal has been at the forefront of disseminating innovative research findings and comprehensive reviews that enhance our understanding of drug therapies and their clinical applications. With an impact factor that reflects its strong reputation and a Scopus ranking placing it in the 64th percentile among 272 journals in medical pharmacology, the journal stands as a critical resource for researchers, healthcare professionals, and students alike. Although currently not an Open Access journal, it provides invaluable insights into therapeutic drug use and safety, the pharmacokinetics of drugs, and the development of new therapeutic strategies. The journal's commitment to advancing the field through high-quality, peer-reviewed articles ensures it remains a vital asset in the continuously evolving landscape of clinical pharmacology.

DRUGS is a prestigious, peer-reviewed journal published by ADIS INT LTD, specializing in the field of pharmacology across diverse medical applications. With an impressive impact factor and ranking as Q1 in the Pharmacology (Medical) category as per the 2023 metrics, this journal consistently exhibits a strong influence in the medical research community, holding a notable rank of #3 out of 272 in its domain on Scopus, placing it within the 99th percentile. Established in 1971 and converging its insightful contributions until 2024, DRUGS encompasses a broad scope, focusing on the latest advancements in drug research, development, and clinical applications, aiming to bridge the gap between laboratory discoveries and therapeutic practices. Though not an Open Access journal, it remains a key resource for researchers, professionals, and students keen on exploring cutting-edge findings and developments in pharmacology. Its location in the United Kingdom further emphasizes its role as a global leader in pharmaceutical sciences.